[go: up one dir, main page]

WO2009147178A2 - Nouvelle utilisation médicale de pyridin-2-ylméthylsulfinyl-1h-benzimidazoles substitués - Google Patents

Nouvelle utilisation médicale de pyridin-2-ylméthylsulfinyl-1h-benzimidazoles substitués Download PDF

Info

Publication number
WO2009147178A2
WO2009147178A2 PCT/EP2009/056824 EP2009056824W WO2009147178A2 WO 2009147178 A2 WO2009147178 A2 WO 2009147178A2 EP 2009056824 W EP2009056824 W EP 2009056824W WO 2009147178 A2 WO2009147178 A2 WO 2009147178A2
Authority
WO
WIPO (PCT)
Prior art keywords
benzimidazole
ylmethylsulphinyl
methylsulphinyl
pyridinyl
substituted pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/056824
Other languages
English (en)
Other versions
WO2009147178A3 (fr
Inventor
Hartmut Heinze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of WO2009147178A2 publication Critical patent/WO2009147178A2/fr
Publication of WO2009147178A3 publication Critical patent/WO2009147178A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Definitions

  • the invention relates to the use of substituted pyridin-2-ylmethylsulphinyl-I H-benzinnidazoles, i.e. proton pump inhibitors, and here especially pantoprazole for the treatment and / or prophylaxis of brain edema.
  • Pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles are well known for their H + /K + -ATPase-inhibitory action. These compounds are, owing to their mechanism of action, also referred to as proton pump inhibitors or, abbreviated, as PPI.
  • PPI proton pump inhibitors
  • Such sulfinyl derivates are described in a variety of patents and patent applications and here especially EP-A-0005129, EP-A-0166287, EP-A-0174726, EP-A- 0254588 and EP-A-0268956 should be mentioned. Compounds as described in these later mentioned patents are of considerable importance in the therapy of disorders associated with an increased secretion of gastric acid.
  • Examples of active compounds from this group which are commercially available or in clinical de- velopment are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H- benzimidazole (INN: omeprazole), (S)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2- pyridinyl)methylsulphinyl]-1 H-benzimidazole (INN: esomeprazole), 5-difluoromethoxy-2- [(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4- (2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole (INN: lansoprazole), 2- ⁇ [4-(3- methoxypropoxy
  • Brain edema (syn cerebral edema, brain swelling etc.) is a condition with substantial mortality, usually subsequent to e.g. head injuries, tumors, brain surgery or vascular events.
  • Current treatment options such as high dose mannitol infusions, corticosteroids or even craniectomy are not optimal therapies.
  • a safe drug that can prevent brain edema or reduce the intracranial pressure and which can be used as mono or combination treatment would be a major advantage and could most probably be life-saving for quite a number of patients who untreated might suffer and eventually die from brain edemas.
  • the invention therefore relates to substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis of brain edema.
  • the invention relates to substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles or a pharmaceutically acceptable salt thereof, for use in the treatment of brain edema.
  • the invention relates to substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles or a pharmaceutically acceptable salt thereof, for use in the prophylaxis of brain edema.
  • the invention further relates to a pharmaceutical composition, comprising a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis of brain edema.
  • the invention also relates to the use of a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/or prophylaxis of brain edema.
  • the invention further relates to a method of treatment or prevention of brain edema comprising administering a therapeutically effective amount of a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole to a patient in need thereof.
  • Cerebral edema may be comprehensively defined as a pathologic increase in the amount of total brain water content leading to an increase in brain volume. This deceivingly simple definition fails to reflect the complex pathophysiological underpinnings of the various forms of cerebral edema that may occur in association with severe neurologic diseases.
  • Edema in the brain may be topographically classified into focal or global.
  • Focal edema generates a pressure gradient with adjacent regions and may result in tissue shift and herniation. Examples of focal edema can be found around tumors, hematomas, and infarctions.
  • Global edema diffusely affects the whole brain and, when critical, it may cause intracranial hypertension, compromise perfusion, and lead to generalized ischemia. Cardiopulmonary arrest, severe traumatic injury, and fulminant liver failure are common causes of global cerebral edema.
  • a different classification based on the pathophysiologic mechanisms responsible for the production of the edema classifies it into 3 types: cytotoxic, vasogenic, and interstitial (for example Rabinstein AA, Treatment of Cerebral Edema, The Neurologist 2006; 12: 59-73).
  • Neurosurgery is a surgical specialty concerned with the treatment of diseases and disorders of the brain, spinal cord, and peripheral and sympathetic nervous system.
  • Head trauma means injury to the head, scalp and cranium that may be limited to soft tissue damage or may include the cranial bones and the brain.
  • the most common causes of head trauma are traffic accidents, sports injuries, falls, workplace accidents, assaults, and bullet wounds.
  • the head may be damaged both from direct physical injury to the brain and from secondary factors. Secondary factors include lack of oxygen, swelling of the brain, and loss of blood flow to the brain.
  • vascular events in the brain are usually referred to as stroke. They occur when blood flow to a region of the brain is disturbed and may result in death of brain tissue. Strokes are a major cause of death and permanent disability. Ischemic stroke is caused by blockage in an artery that supplies blood to the brain, resulting in a deficiency in blood flow (ischemia). Hemorrhagic stroke is caused by the bleeding of ruptured blood vessels (hemorrhage) in the brain.
  • brain edema shall be defined to include pathologic effects to the brain resulting from neurosurgery, head trauma, fulminant liver failure or vascular events, as outlined in detail above.
  • the compounds can exist as a racemic mixture of enantiomers, a mixture of the corresponding enantiomers independent of their ratio, or an enantiomer being substantially free of the other enantiomer.
  • the substituted pyridin-2-ylmethylsulphinyl-1H-benzimidazole is a compound selected from 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, (S)-5- methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, (S)-5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, 2-[3-methyl-4- (2, 2, 2-trifluoroethoxy)-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole,
  • substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles are compounds wherein at least one of the hydrogen atoms of one or more substitutents at the benzimidazole or at the pyridinyl moiety of the chemical structure of the compound is substituted by a deuterium atom.
  • at least one of the hydrogen atoms of the substituent at the 4-position of the pyridinyl moiety of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is substituted by a deuterium atom.
  • the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5-difluoromethoxy- 2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole or (S)-5-difluoromethoxy-2- [(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole and pharmaceutically acceptable salts thereof.
  • substantially free in the context of the invention means that a compound with (S)-configuration and/or its salt contains less than 10 % by weight of a compound with (R)-configuration and/or its salt.
  • substantially free means that a compound with (S)-configuration and/or its salt contains less than 5 % by weight of a compound with (R)-configuration and/or its salt. More preferably, “substantially free” means that a compound with (S)-configuration and/or its salt contains less than 2 % by weight of a compound with (R)-configuration and/or its salt. In the most preferred embodiment, “substantially free” means that a compound with (S)-configuration and/or its salt contains less than 1 % by weight of a compound with (R)-configuration and/or its salt.
  • Salts of substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles include all inorganic and organic acid addition salts and salts with bases, especially all pharmaceutically acceptable inorganic and organic acid addition salts and salts with bases, particularly all pharmaceutically acceptable inorganic and organic acid addition salts and salts with bases customarily used in pharmacy.
  • salts with bases include, but are not limited to, lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, ammonium, meglumine and guanidinium salts. Of these, sodium and magnesium are preferred.
  • Preferred embodiments of the invention might be the sodium salt of 5-difluoromethoxy-2- [(3, 4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, the sodium salt of (S)-5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, the magnesium salt of 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole or the magnesium salt of (S)-5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H- benzimidazole.
  • Another embodiments of the invention are also the sodium salt of 5-methoxy-2-[(4-methoxy-3,5- dimethyl-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole and the magnesium salt of (S)-5-methoxy- 2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole.
  • the salts of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles may additionally contain water molecules.
  • Examples for such hydrated salts are sodium 5-difluoromethoxy-2-[(3,4-dimethoxy-2- pyridinyl)methylsulphinyl]-1 H-benzimidazole monohydrate or sesqui hydrate, magnesium bis(5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole) dihydrate, or magnesium bis((S)-5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H- benzimidazole) dihydrate.
  • a pharmaceutical composition can be formulated comprising the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole together with at least one pharmaceutically acceptable auxiliary.
  • auxiliaries any auxiliaries known to be suitable for preparing pharmaceutical compositions can be used. Examples thereof include, but are not limited to, solvents, excipients, dispersants, emulsifiers, solubilizers, gel formers, ointment bases, antioxidants, preservatives, stabilizers, carriers, fillers, binders, thickeners, complexing agents, disintegrating agents, buffers, permeation promoters, polymers, lubricants, coating agents, propellants, tonicity adjusting agents, surfactants, colorants, flavorings, sweeteners and dyes.
  • auxiliaries of a type appropriate to the desired formulation and the desired mode of administration are used.
  • compositions can be formulated, for example, into tablets, coated tablets (dragees), pills, cachets, capsules (caplets), granules, powders, suppositories, solutions (e.g. sterile solutions), emulsions, suspensions, ointments, creams, lotions, pastes, oils, gels, sprays and patches (e.g. transdermal therapeutic systems).
  • compositions comprising the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole and at least one auxiliary can be manufactured in a manner known to a person skilled in the art, e.g. by dissolving, mixing, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • the pharmaceutical compositions can contain a substituted pyridin-2-ylmethylsulphinyl-I H-benzimidazole or pharmaceutically acceptable salts thereof as the active compound in a total amount of from 0.1 to 99.9 wt%, preferably 5 to 95 wt%, more preferably 20 to 80 wt%.
  • the selected formulation depends inter alia on the route of administering the pharmaceutical composition.
  • the pharmaceutical compositions can be administered preferably by any suitable route, but preferably by the oral, intravenous and/or intraarterial route.
  • Tablets, coated tablets (dragees), pills, cachets, capsules (caplets), granules, solutions, emulsions and suspensions are e.g. suitable for oral administration.
  • said formulations can be adapted so as to represent, for example, an enteric form, an immediate release form, a delayed release form, a repeated dose release form, a prolonged release form or a sustained release form.
  • Said forms can be obtained, for example, by coating tablets, by dividing tablets into several compartments separated by layers disintegrating under different conditions (e.g. pH conditions) or by coupling the active compound to a biodegradable polymer.
  • parenteral modes of administration such as, for example, intravenous, intraarterial, intramuscular, subcutaneous, intracutaneous, intraperitoneal and intrasternal administration
  • solutions e.g. sterile solutions, isotonic solutions
  • they are preferably administered by injection or infusion techniques.
  • the pharmaceutical composition can be administered in a single dose per day or in multiple subdoses, for example, 2 to 4 doses per day. In case of parental modes of administration, e.g. intraveneous administration continuous administration is preferred, especially if multiple doses are needed.
  • a single dose unit of the pharmaceutical composition can contain e.g. from 0.01 mg to 200 mg, preferably 0.1 mg to 150 mg, more preferably 0.5 mg to 100 mg, most preferably 1 mg to 80 mg, of the active compound.
  • Another embodiment of the invention is an use of substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles in the manufacture of pharmaceutical compositions for the treatment and/ or prophylaxis of brain edema wherein the medicament is administered following a defined scheme.
  • the (weight) amounts of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles as given below refer to the free form of the compounds. If a salt form or a hydrated salt form of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is to be administered instead, the (weight) amount of the salt form or hydrated salt form used has to be adapted, i.e. increased accordingly.
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/ or prophylaxis of brain edema, following an administration regime of a) administering a pharmaceutical composition which contains 40 mg or at least 40 mg of the sustituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit at least twice daily with the provisio that the pharmaceutical composition can be administered to the patient perorally for a remaining period up to 28, preferably 14 days following the administration regime according to step a).
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/ or prophylaxis of brain edema, following an administration regime of a) administering a pharmaceutical composition which contains 80 mg of the sustituted pyridin- 2-ylmethylsulphinyl-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit at least twice daily with the provisio that the pharmaceutical composition can be administered to the patient perorally for a remaining period up to 28, preferably 14 days following the administration regime according to step a).
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/or prophylaxis of brain edema, wherein the pharmaceutical composition is prepared for a) administering a pharmaceutical composition which contains 40 mg or at least 40 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit at least twice daily with the provisio that the pharmaceutical composition can be administered to the patient perorally for a remaining period up to 28, preferably 14 days following the administration regime according to step a).
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/or prophylaxis of brain edema, wherein the pharmaceutical composition is prepared for a) administering a pharmaceutical composition which contains 80 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit at least twice daily with the provisio that the pharmaceutical composition can be administered to the patient perorally for a remaining period up to 28, preferably 14 days following the administration regime according to step a).
  • a method of treatment and/or prevention of brain edema comprising administering a therapeutically effective amount of a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole to a patient in need thereof, comprising the steps of a) administering a pharmaceutical composition which contains 40 mg or at least 40 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit at least twice daily with the provisio that the pharmaceutical composition can be administered to the patient perorally for a remaining period up to 28, preferably 14 days following the administration regime according to step a).
  • a method of treatment and/or prevention of brain edema comprising administering a therapeutically effective amount of a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole to a patient in need thereof, comprising the steps of a) administering a pharmaceutical composition which contains 80 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole in a single unit at least twice daily with the provisio that the pharmaceutical composition can be administered to the patient perorally for a remaining period up to 28, preferably 14 days following the administration regime according to step a).
  • the substituted pyridin-2-ylmethylsulphinyl-1H-benzimidazole is a compound selected from 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, (S)-5- methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, (S)-5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, 2-[3-methyl-4- (2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole,
  • the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is a compound selected from 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H- benzimidazole, (S)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H- benzimidazole, 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H- benzimidazole, (S)-5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H- benzimidazole and pharmaceutically acceptable salts thereof.
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis of brain edema wherein the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5-difluoromethoxy-2-[(3,4-dimethoxy-2- pyridinyl)methylsulphinyl]-1 H-benzimidazole, following an administration regime of a) administering a pharmaceutical composition which contains 40 mg or at least 40 mg of 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days, b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of 5- difluoromethoxy-2-[(3,4-dimeth
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis of brain edema wherein the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5-difluoromethoxy-2-[(3,4-dimethoxy-2- pyridinyl)methylsulphinyl]-1 H-benzimidazole, following an administration regime of a) administering a pharmaceutical composition which contains 80 mg of 5-difluoromethoxy-2- [(3, 4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days, b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyri
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/ or prophylaxis of brain edema, wherein the the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5-difluoromethoxy-2-[(3,4-dimethoxy-2- pyridinyl)methylsulphinyl]-1 H-benzimidazole, following an administration regime of a) administering a pharmaceutical composition which contains 40 mg or at least 40 mg of 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of 5- difluorome
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/ or prophylaxis of brain edema, wherein the the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5-difluoromethoxy-2-[(3,4-dimethoxy-2- pyridinyl)methylsulphinyl]-1 H-benzimidazole, following an administration regime of a) administering a pharmaceutical composition which contains 80 mg of 5-difluoromethoxy-2- [(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of 5- difluoromethoxy-2-
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/or prophylaxis of brain edema, wherein the the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5-difluoromethoxy-2-[(3,4-dimethoxy-2- pyridinyl)methylsulphinyl]-1 H-benzimidazole, and wherein the pharmaceutical composition is prepared for a) administering a pharmaceutical composition which contains 40 mg or at least 40 mg of 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of 5-
  • a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions for the treatment and/or prophylaxis of brain edema, wherein the the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5-difluoromethoxy-2-[(3,4-dimethoxy-2- pyridinyl)methylsulphinyl]-1 H-benzimidazole, and wherein the pharmaceutical composition is prepared for a) administering a pharmaceutical composition which contains 80 mg of 5-difluoromethoxy-2- [(3, 4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of 5- difluorometh
  • a method of treatment or prevention of brain edema comprising administering a therapeutically effective amount of a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole to a patient in need thereof, wherein the the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, comprising the steps of: a) administering a pharmaceutical composition which contains 40 mg or at least 40 mg of 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of 5- difluoromethoxy-2-[
  • a method of treatment or prevention of brain edema comprising administering a therapeutically effective amount of a substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole to a patient in need thereof, wherein the the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole is 5- difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole, comprising the steps of: a) administering a pharmaceutical composition which contains 80 mg of 5-difluoromethoxy-2- [(3, 4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole in a single unit intraveneously at least twice daily for a period of at least three days and up to 28, preferably 14 days; and b) administering a pharmaceutical composition which contains either 20 mg or 40 mg of 5- difluoromethoxy-2-[(3,4-d
  • a single unit of the substituted pyridin-2-ylmethylsulphinyl-1 H-benzimidazole as administered to the patient in step b) is suitably provided as a peroral pharmaceutical composition, advantageously in an enteric coated form.
  • pantoprazole in the prevention of stress induced upper gastrointestinal bleeding in neurosurgical or head trauma patients it was observed that a statistically significant effect on the reduced occurrence of brain edema can be achieved.
  • pantoprazole 80 mg was given intravenous every 12 hours and continued thereafter until a peroral intake was initiated.
  • the peroral dosage regime was pantoprazole 40 mg every 12 hours until day 14 of the study.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur une nouvelle utilisation de pyridyl-2-méthylsulfinylbenzimidazoles substitués pour le traitement et/ou la prophylaxie d'un oeème cérébral.
PCT/EP2009/056824 2008-06-04 2009-06-03 Nouvelle utilisation médicale de pyridin-2-ylméthylsulfinyl-1h-benzimidazoles substitués Ceased WO2009147178A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08157528 2008-06-04
EP08157528.4 2008-06-04

Publications (2)

Publication Number Publication Date
WO2009147178A2 true WO2009147178A2 (fr) 2009-12-10
WO2009147178A3 WO2009147178A3 (fr) 2010-03-18

Family

ID=39870104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/056824 Ceased WO2009147178A2 (fr) 2008-06-04 2009-06-03 Nouvelle utilisation médicale de pyridin-2-ylméthylsulfinyl-1h-benzimidazoles substitués

Country Status (1)

Country Link
WO (1) WO2009147178A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495018B2 (en) * 2000-03-30 2009-02-24 Takeda Pharmaceutical Company Limited Substituted 1,3-thiazole compounds, their production and use
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
WO2009147178A3 (fr) 2010-03-18

Similar Documents

Publication Publication Date Title
ES2687985T3 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer colorrectal
KR102061052B1 (ko) 야간 산 분비에 대한 벤즈이미다졸 유도체의 용도
JP2011509301A5 (fr)
ES2996895T3 (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
JP2003512327A (ja) 置換ベンズイミダゾール製剤
JP2025122089A (ja) ベンズイミダゾール誘導体化合物を含む医薬組成物
AU2005204014B2 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
US20120122919A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
US20110152314A1 (en) Use of tenatoprazole for the treatment of gastroesophageal reflux disease
WO2009147178A2 (fr) Nouvelle utilisation médicale de pyridin-2-ylméthylsulfinyl-1h-benzimidazoles substitués
WO2004045612A1 (fr) Utilisation d'un inhibiteur de la pompe a protons pour prevenir les nausees et les vomissements postoperatoires
KR101460828B1 (ko) 두개골 외상의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도
TW200920371A (en) A combination treatment
WO2017121383A1 (fr) Utilisation de la pirenzépine pour traiter la septicémie
KR20150135110A (ko) p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물
KR20140116879A (ko) (3s,3s'') 4,4''-디설판디일비스(3-아미노부탄 1-설폰산) 및 제2 항고혈압제의 조합
WO2011027021A1 (fr) Procédé de traitement de l'hypertension
TW202535366A (zh) 達羅他胺(darolutamide)組合braf及mek抑制劑以用於黑色素瘤之治療
JPWO2002092096A1 (ja) 抗腫瘍剤
Kumar et al. A study on the use of dexmedetomidine as an adjuvant to local anaesthesia for tympanoplasty
WO2003077916A1 (fr) Utilisation d'inhibiteurs de la pompe a protons pour le traitement de douleurs thoraciques d'origine non cardiaque
WO2003072136A1 (fr) Compositions antihypertensives et leurs utilisations
RU2516922C2 (ru) Фармацевтические композиции, содержащие s-амлодипина никотинат и их применение в лечении цереброваскулярных нарушений
Wong et al. Esomeprazole: a new proton pump inhibitor for NSAID-associated peptic ulcers and dyspepsia
MX2015002646A (es) Otamixaban para uso en el tratamiento de sindrome coronario agudo sin elevacion de st en pacientes programados para ser sometidos a injerto de bypass de arteria coronaria.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09757559

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09757559

Country of ref document: EP

Kind code of ref document: A2